Market Cap (In USD)
378.24 Thousand
Revenue (In USD)
-
Net Income (In USD)
-4.79 Million
Avg. Volume
111.25 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.2918-0.3481
- PE
- -
- EPS
- -
- Beta Value
- 1.816
- ISIN
- CA10778Y1126
- CUSIP
- -
- CIK
- 1610820
- Shares
- 3708323.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. William V. Williams M.D.
- Employee Count
- -
- Website
- https://briacell.com
- Ipo Date
- Details
- BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
More Stocks
-
VLTTFVolatus Aerospace Corp.
VLTTF
-
CLE
-
IPHIPH Limited
IPH
-
WEBELSOLARWebsol Energy System Limited
WEBELSOLAR
-
MS-PFMorgan Stanley
MS-PF
-
VIKASLIFEVikas Lifecare Limited
VIKASLIFE
-
IPG
-
AGNCLAGNC Investment Corp.
AGNCL